Future Perspective of Chemotherapy and Pharmacotherapy in Thymic Carcinoma
Open Access
Abstract
Thymic carcinoma is a rare cancer that arises from thymic epithelial cells. Its nature and pathology differ from that of benign thymoma, presenting a poorer prognosis. If surgically resectable, surgery alone or surgery followed by chemoradiotherapy or radiotherapy is recommended by the National Comprehensive Cancer Network Guidelines. Metastatic and refractory thymic carcinomas require systemic pharmacotherapy. Combined carboplatin and paclitaxel, and cisplatin and anthracycline-based regimens have been shown a fair response rate and survival to provide a de facto standard of care when compared with other drugs employed as first-line chemotherapy. Cytotoxic agents have been pivotal for treating thymic carcinoma, as little is known regarding its tumorigenesis. In addition, genetic alterations, including driver mutations, which play an important role in treatments, have not yet been discovered. However, molecular pathways and biomarker studies assessing thymic epithelial tumors have been reported recently, resulting in the development of new agents, such as molecular targeted agents and immune checkpoint inhibitors. As treatment options are currently limited and the prognosis remains poor in metastases and recurrent thymic carcinoma, genetic alterations need to be assessed. In the present review, we focused on the current role of targeted therapies and immune checkpoint inhibitors in treating thymic carcinoma.Keywords
This publication has 98 references indexed in Scilit:
- The C-Kit Receptor-Mediated Signal Transduction and Tumor-Related DiseasesInternational Journal of Biological Sciences, 2013
- Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumorsCell Death & Disease, 2012
- Rare cancers are not so rare: The rare cancer burden in EuropeEuropean Journal of Cancer, 2011
- Phase II Study of Carboplatin and Paclitaxel in Advanced Thymoma and Thymic CarcinomaJournal of Clinical Oncology, 2011
- Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial TumorsJournal of Clinical Oncology, 2011
- Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutationLung Cancer, 2011
- Insulin‐like growth factor‐1 receptor and phosphorylated AKT‐serine 473 expression in 132 resected thymomas and thymic carcinomasCancer, 2010
- Sunitinib in metastatic thymic carcinomas: Laboratory findings and initial clinical experienceBritish Journal of Cancer, 2010
- Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and ThymomasClinical Cancer Research, 2009
- Long-term survival and prognostic factors in thymic epithelial tumours☆European Journal of Cardio-Thoracic Surgery, 2004